2',4'-dihydroxychalcone, a flavonoid isolated from Herba oxytropis, suppresses PC-3 human prostate cancer cell growth by induction of apoptosis

Oncology Letters
Yuqing ShengQiheng Li

Abstract

Natural products are a promising source for the development of novel cancer therapies, due to their potential effectiveness and low toxicity profiles. As a main component of Herba oxytropis, 2',4'-dihydroxychalcone (TFC) is known to demonstrate anti-tumor activity in vitro. In the present study, TFC was found to potently inhibit proliferation and induce apoptosis in PC-3 human prostate cancer cells in a dose-dependent manner. The results demonstrated that the induction of apoptosis is associated with cell cycle arrest at the G0/G1 phase and activation of caspase-3/-7. Additional mechanistic studies of two biomarkers, phosphatase and tensin homolog (PTEN) and cyclin-dependent kinase inhibitor 1B (p27(Kip1)), in prostate cancer revealed that TFC treatment significantly upregulated the expression of PTEN and p27(Kip1). The findings of the present study indicate that TFC-induced apoptosis in PC-3 cells via upregulation of PTEN and p27(Kip1), which results in cell cycle arrest in G0/G1 phase, activation of caspase-3/-7 and induction of apoptosis. Therefore, TFC may be a potential compound for human prostate cancer therapy.

References

Sep 10, 1998·Journal of the National Cancer Institute·C Cordon-CardoH I Scher
Apr 14, 1999·Cell Death and Differentiation·A G Porter, R U Jänicke
Aug 24, 1999·Cancer Metastasis Reviews·E Macri, M Loda
Nov 27, 2001·Bioorganic & Medicinal Chemistry Letters·C PougetA J Chulia
Jan 25, 2002·Annals of the New York Academy of Sciences·O W BrawleyH Parnes
Jan 30, 2004·Proceedings of the National Academy of Sciences of the United States of America·Stéphanie A BackmanTak W Mak
Jul 12, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·James A Crowell
Oct 29, 2005·Planta medica·Jih-Jung ChenIh-Sheng Chen
Aug 30, 2008·Sub-cellular Biochemistry·Sahar A SaddoughiBesim Ogretmen
May 22, 2009·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Chenghua LouBaochang Cai
May 18, 2010·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Chenghua LouBaochang Cai
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Sep 29, 2011·Journal of Experimental & Clinical Cancer Research : CR·Rebecca S Y Wong
Jun 5, 2012·Frontiers in Endocrinology·Yanqiu LiuShidong Jia
Sep 14, 2012·Expert Opinion on Therapeutic Patents·Sônia S CostaFrederico A Vanderlinde
Nov 29, 2013·International Journal of Molecular Sciences·Feng XieLiqun Zhou
Jan 9, 2014·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis